Foley & Lardner
Foley & Lardner LLP is an international law firm started in 1842. According to The American Lawyer, the firm ranked 35th on The American Lawyer's 2009 AmLaw 100 rankings of U.S. law firms, with $731,000,000 in gross revenue in 2008. Foley & Lardner has been in The American Lawyer's annual AmLaw 100 rankings of U.S. law firms by revenue since 1986.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying Carried Out by Foley & Lardner
Names of Lobbyists
Client Amount National Concrete Masonry Assn $290,000 Canadian National Railway $260,000 Hanger Orthopedic Group $240,000 Shoreland Inc $240,000 EmCare Inc $230,000 Great Lakes Higher Education Corp $210,000 Integrys Energy Group $150,000 Kinecta Federal Credit Union $140,000 Sittercity $130,000 Gottfried Kellermann $120,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Fed Budget & Appropriations,
- Energy & Nuclear Power,
- Labor, Antitrust & Workplace,
- Environment & Superfund,
- Homeland Security,
- Medical Research & Clin Labs,
Most Frequently Disclosed Bills
Bill No. Title H.R.3395 Concrete Masonry Products Research, Education, and Promotion Act of 2011 H.R.4123 Fair Playing Field Act of 2012 S.2145 Fair Playing Field Act of 2012 S.2252 Rebuild America Act H.R.2575 Prosthetic and Custom Orthotic Parity Act of 2009 S.3223 Prosthetics and Custom Orthotics Parity Act of 2010 S.3517 Claims Processing Improvement Act of 2010 S.3786 Fair Playing Field Act of 2010 H.R.6128 Fair Playing Field Act of 2010
Recent Lobbying Contracts
Date Client Summary June 3, 2013 RDK Enterprises, LLC Water purification project View registration April 22, 2013 Oakland Transportation Holdings LLC Expansion of Brookhaven Rail Terminal View registration
RegulationsMentioned in 20 dockets; Submitted to 4 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Foley & Lardner" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Foley & Lardner
- Toggle 1 IRS Taxable Medical Devices 2012
- Toggle 1 IRS Additional Requirements for Charitable Hospitals 2012
- Toggle 1 FDA Permit the Filing of Abbreviated New Drug Applications for Sodium Chloride in Plastic Syringes 2012
- Toggle 1 FDA Issue a Determination That The Drug Product Fundescein-25, Fluorescein Sodium Injection 25% Was Not Voluntarily Withdrawn For Sale For Safety or Effectiveness Reasons - CLOSED 2011
Mentions in Document Text
View all mentions data for Foley & Lardner
- Toggle 4 FDA Issue a Determination That The Drug Product Fundescein-25, Fluorescein Sodium Injection 25% Was Not Voluntarily Withdrawn For Sale For Safety or Effectiveness Reasons - CLOSED 2011
- Toggle 4 FDA Issue a Timely Response to Intendis' August 13, 2010 Comments on the May 2010 Draft Guidance on Azelaic Acid-CLOSED 2011
- Toggle 3 FDA Stay the Approval of any Pending Abbreviated New Drug Applications or New Drug Applications for Single Entity Products Containing Oxycodone Hydrochloride Unless the Conditions Specified in the Petition are Satisfied - CLOSED 2011
- Toggle 3 FDA Patent Term Extension Application for TEFLARO™ (ceftaroline fosamil) U.S. Patent No. 6,906,055 2011
- Toggle 3 FDA Patent Term Extension Application for TEFLARO™ (ceftaroline fosamil) U.S. Patent No. 6,417,175 2011
- Toggle 3 FDA Permit the Filing of Abbreviated New Drug Applications for Sodium Chloride in Plastic Syringes 2012
- Toggle 2 FDA Determine that Dexmedetomidine Hydrochloride Injection in a 400mcg/4mL Vial Suitable for Submission as an Abbreviated New Drug Application (ANDA) 2012
- Toggle 2 EPA Reconsideration of Portland Cement NESHAP and NSPS 2011
- Toggle 2 FDA Not Approve Any Acetylcysteine Injection Abbreviated New Drug Application for Which Acetadote® is The Reference Listed Drug if The Generic Drug Product Contains Edetate Disodium as a Component of Its Formulation 2012
- Toggle 1 FDA Make a Determination That The Discontinued Formulation of The Reference Listed Drug Acetadote® (acetylcysteine) Injection, The Subject of NDA 21-539, Held by Cumberland Pharmaceuticals, Inc. is Suitable for Submission in an Abbreviated New Drug Application (ANDA) 2011
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Foley & Lardner" that sat on federal advisory committees.
- Toggle Office of the United States Trade Representative 1 person on 1 committee